On Tuesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Neuralstem, Inc. (NYSEMKT:CUR), RLJ Lodging Trust (NYSE:RLJ), Rovi Corporation (NASDAQ:ROVI), Paramount Group, Inc. (NYSE:PGRE)

Neuralstem, Inc. (NYSEMKT:CUR), with shares declined -5.06 %, closed at $2.25.

RLJ Lodging Trust (NYSE:RLJ), with shares dropped -2.06%, settled at $31.82.

Rovi Corporation (NASDAQ:ROVI), with shares dipped -4.95%, and closed at $20.92.

Paramount Group, Inc. (NYSE:PGRE), plummeted -2.05%, and closed at $19.15.

Latest NEWS regarding these Stocks are depicted underneath:

Neuralstem, Inc. (NYSEMKT:CUR)

Last week, on Monday, Neuralstem, Inc. (CUR), stated its financial results for the fourth quarter and year ended December 31, 2014.

2014 Business Highlights:

Board of Directors: Neuralstem designated two independent directors to its Board of Directors in 2014, Catherine Angell Sohn, Pharm.D. and Sandford Drexel Smith. Dr. Sohn is the former Senior Vice President of Business Development and Planned Alliance, GSK Consumer Healthcare, at GlaxoSmithKline. Mr. Smith is the former Executive Vice President of Genzyme Corporation.

Financial: In January 2014, Neuralstem closed a $20 million registered direct offering with proceeds intended to fund its ongoing clinical trials and corporate operations.

Financial Results for the Year Ended December 31, 2014:

Cash, cash equivalents and short-term investments on hand was about $27.5 million at December 31, 2014, contrast to about $16.8 million at December 31, 2013. The raise was primarily due to their raising about $19.5 million, net, through the sale of our ordinary stock and warrants, and about $4.2 million, net, from their October 2014 debt amendment transaction, partially offset by cash used in their operations.

In the year ended December 31, 2014, they stated a net loss of about $22.6 million or $0.26 per share, contrast to a loss of about $19.8 million or $0.27 per share in the year ended December 31, 2013. Their operating loss in the year ended December 31, 2014 was about $17.4 million, contrast to a loss of about $12.5 million in the year ended December 31, 2013. The rise in operating loss was primarily attributable to a raise of about $3.7 million in general and administrative expenses coupled with a raise of about $1.0 million in research and development expenses.

The raise in research and development expenses was primarily attributable to a raise of about $0.7 million in payroll and related expenses due to raised salaries and headcount, a raise of about $0.1 million in project and lab expenses and an raise of about $0.1 million in travel and related expenses due to their clinical trial activities. These raised expenses are all related to a ramping-up of their pre-clinical and clinical trial efforts and are predictable to continue into subsequent periods.

The raise in general and administrative expenses was primarily attributable to a raise of about $2.0 million in non-cash stock based compensation expenses primarily related to financial advisory and consultant services’ achieving a performance based milestone that resulted in a term extension of certain ordinary stock purchase warrants, a raise of about $1.0 million in legal and professional fees related to patent, litigation and other corporate matters, a raise of about $0.6 million in consulting fees primarily related to new business development efforts and an raise of about $0.2 million in payroll and related expenses due to current year headcount raises.

In addition, in the year ended December 31, 2014 the company recorded about $5.2 million of other expenses, primarily comprised of about $3.1 million related to their extension of certain ordinary stock purchase warrants, about $1.6 million of interest expenses principally related to their long-term debt, a loss of about $0.4 million on their debt amendment transaction and about $0.3 million related to the change in fair value of the Corporation’s warrant liabilities, partially offset by about $0.3 million of revenue from a milestone payment from a legal settlement.

Neuralstem, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds.

RLJ Lodging Trust (NYSE:RLJ)

Formerly on March 13, RLJ Lodging Trust (RLJ), declared that its Board of Trustees declared a regular quarterly cash dividend of $0.33 per ordinary share of beneficial interest. The dividend is payable on April 15, 2015, to shareholders of record as of March 31, 2015.

The Corporation’s first quarter dividend represents an raise of $0.03, or 10%, over the preceding quarter’s cash dividend. Based on the Corporation’s ordinary stock closing price of $30.74 on March 12, 2015, the annualized $1.32 dividend represents a 4.3% yield.

RLJ Lodging Trust is an independent equity real estate investment trust. The firm also manages real estate funds. It invests in the real estate markets of the United States.

Rovi Corporation (NASDAQ:ROVI)

Rovi Corporation (ROVI), declared the appointment of Steven Lucas to its Board of Directors, effective March 20, 2015. This appointment expands the size of the Board from six to seven directors.

Andrew Ludwick, Chairman of the Board and chairman of Rovi’s Corporate Governance and Nominating Committee, said “Steve is a seasoned veteran of the technology industry with an impressive record of accomplishment at the highest levels of leading companies. He brings a powerful mix of exactly the right ingredients to fuel Rovi’s forward momentum. His expertise in analytics will be particularly valuable as Rovi continues to leverage our prominent guide footprint to assist customers understand, analyze and monetize their cross-platform audiences. The market for advanced data and analytics services is large and growing, and Rovi has made noteworthy progress in the last 12 months alone by introducing new customers to our advertising and analytics platforms to generate added proceed both for customers and for Rovi. Having thoroughly reviewed a broad range of highly qualified candidates and sought input from a number of our stockholders, the Committee enthusiastically recommended Steve’s appointment to the Board.”

As part of Rovi’s ongoing effort to augment the Corporation’s Board of Directors with expertise in key planned areas, Rovi’s Corporate Governance and Nominating Committee conducted an extensive search process with the assistance of Howard Fischer Associates, a leading professional search firm and identified, interviewed and evaluated a wide range of candidates.

Rovi Corporation provides integrated solutions for the discovery and personalization of digital entertainment to service providers and consumer electronics (CE) industry worldwide. The corporation offers interactive program guides (IPGs), an interactive listing of television or video program information that enables viewers to navigate through, sort, select, and plan video programming for viewing and recording. It markets IPGs to service providers under i-Guide and Passport brands; and CE industry under the G-GUIDE and HTML Guide brands.

Paramount Group, Inc. (NYSE:PGRE)

Formerly on March 5, Paramount Group, Inc. (PGRE), a fully-integrated real estate investment trust focused on owning, operating and managing high-quality, Class A office properties in select central business district submarkets of New York City, Washington, D.C. and San Francisco, stated results for the quarter ended December 31, 2014. The Corporation commenced its operations on November 24, 2014 upon completion of its initial public offering and related formation transactions. The financial results for the fourth quarter of 2014 represent the Corporation’s financial results for the 38 day period from November 24, 2014 to December 31, 2014.

Noteworthy Fourth Quarter Events comprised of:

• Raised $2.6 billion in gross proceeds in the IPO.
• Reached a $1.0 billion senior unsecured revolving credit facility, with an accordion feature to raise the availability to $1.25 billion under certain circumstances.
• Executed 23 leases aggregating 537,000 square feet at a weighted average initial rent of $72.24 per square foot.
• Raised portfolio occupancy to 93.9% at December 31, 2014, up 180 basis points from September 30, 2014.
• Stated Core Funds from Operations (“Core FFO”) attributable to Paramount Group, Inc. of $16.1 million, or $0.08 per diluted share for the period from November 24, 2014 to December 31, 2014.
• Accomplished the initial closing of Paramount Group Real Estate Fund VIII, a private equity real estate fund that the Corporation sponsored (targeting debt and preferred equity investments), with $485.0 million of capital commitments.

Financial Results for the Period from November 24, 2014 to December 31, 2014:

Net revenue attributable to ordinary stockholders was $57.3 million, or $0.27 per diluted share for the period from November 24, 2014 to December 31, 2014. Net revenue for the period from November 24, 2014 to December 31, 2014 comprises (i) a $239.7 million gain on consolidation of a partially owned entity and (ii) $15.1 million of unrealized gains on interest rate swaps, partially offset by (iii) $143.4 million of expenses in connection with attainment, transaction and formation related costs and (iv) $25.7 million of defeasance and debt breakage costs.

Core FFO attributable to Paramount Group was $16.1 million, or $0.08 per diluted share for the period from November 24, 2014 to December 31, 2014. Core FFO excludes the influence of the gain on consolidation of a partially owned entity, attainment, transaction and formation related costs, defeasance and debt breakage costs, and unrealized gains on interest rate swaps.

Paramount Group, Inc. is based in the United States.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.